NZ595364A - TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC beta-CELL DYSFUNCTION - Google Patents

TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC beta-CELL DYSFUNCTION

Info

Publication number
NZ595364A
NZ595364A NZ595364A NZ59536410A NZ595364A NZ 595364 A NZ595364 A NZ 595364A NZ 595364 A NZ595364 A NZ 595364A NZ 59536410 A NZ59536410 A NZ 59536410A NZ 595364 A NZ595364 A NZ 595364A
Authority
NZ
New Zealand
Prior art keywords
treatment
cell dysfunction
pancreatic beta
tissue kallikrein
kallikrein
Prior art date
Application number
NZ595364A
Other languages
English (en)
Inventor
Mark Williams
Kevin Richardson
Original Assignee
Diamedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diamedica Inc filed Critical Diamedica Inc
Publication of NZ595364A publication Critical patent/NZ595364A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ595364A 2009-03-25 2010-03-25 TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC beta-CELL DYSFUNCTION NZ595364A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16317309P 2009-03-25 2009-03-25
PCT/CA2010/000413 WO2010108262A1 (en) 2009-03-25 2010-03-25 TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC β-CELL DYSFUNCTION

Publications (1)

Publication Number Publication Date
NZ595364A true NZ595364A (en) 2013-09-27

Family

ID=42780097

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ595364A NZ595364A (en) 2009-03-25 2010-03-25 TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC beta-CELL DYSFUNCTION

Country Status (8)

Country Link
US (1) US20120070425A1 (https=)
EP (1) EP2411042A4 (https=)
JP (1) JP2012521366A (https=)
CN (1) CN102438648A (https=)
AU (1) AU2010228068A1 (https=)
CA (1) CA2756801A1 (https=)
NZ (1) NZ595364A (https=)
WO (1) WO2010108262A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2182978A4 (en) 2007-07-20 2012-03-21 Sanomune Inc TISSUE KALLIKREIN FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID PROTEIN
EP2720703A4 (en) * 2011-06-17 2015-07-22 Univ Johns Hopkins METHOD FOR INCREASING INSULIN SENSITIVITY AND TREATING DIABETES
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
EP2854841B1 (en) 2012-06-04 2017-02-22 Diamedica Inc. Human tissue kallikrein 1 glycosylation isoforms
CN109498815B (zh) * 2013-12-30 2022-07-22 江苏众红生物工程创药研究院有限公司 重组人激肽释放酶的化学修饰物及其应用
CN110446501A (zh) 2017-03-09 2019-11-12 代阿麦迪卡股份有限公司 组织激肽释放酶1的剂型
CN112481268B (zh) * 2021-01-25 2024-01-30 河南大学 一种棉花启动子PGhPGF及其重组载体和应用
CN116135973A (zh) * 2021-11-16 2023-05-19 江苏众红生物工程创药研究院有限公司 低糖基化修饰的激肽原酶及其聚乙二醇修饰物和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
JP2002516261A (ja) * 1998-05-22 2002-06-04 エンターメッド インコーポレイテッド セリンプロテアーゼを利用して内皮細胞増殖を阻害し血管新生を調節するための組成物と方法
CN1228447C (zh) * 2001-02-20 2005-11-23 深圳市人民医院 一种含有人胰腺组织激肽释放酶成熟蛋白基因的重组表达载体
CN100338212C (zh) * 2003-01-29 2007-09-19 中国科学院大连化学物理研究所 人组织激肽释放酶的微囊化细胞及其微囊化方法和应用
CA2575791A1 (en) * 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
CN101094869A (zh) * 2004-08-03 2007-12-26 戴埃克斯有限公司 Hk1结合蛋白
CA2659012A1 (en) * 2006-07-26 2008-01-31 Diamedica Inc. Methods of diagnosis and treatment for metabolic disorders
JP5322935B2 (ja) * 2006-07-31 2013-10-23 アクティベサイト ファーマシューティカルズ インコーポレイティッド 血漿カリクレインの阻害薬
CN101134953B (zh) * 2007-07-02 2011-02-09 广东天普生化医药股份有限公司 重组人胰激肽原酶
CN101255438B (zh) * 2008-04-11 2012-01-25 深圳大学 表达人组织激肽释放酶的转基因莱茵衣藻的构建方法

Also Published As

Publication number Publication date
JP2012521366A (ja) 2012-09-13
AU2010228068A1 (en) 2011-10-20
CA2756801A1 (en) 2010-09-30
US20120070425A1 (en) 2012-03-22
EP2411042A4 (en) 2012-12-12
WO2010108262A1 (en) 2010-09-30
EP2411042A1 (en) 2012-02-01
CN102438648A (zh) 2012-05-02

Similar Documents

Publication Publication Date Title
NZ595364A (en) TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC beta-CELL DYSFUNCTION
IL201479A (en) Use of tapentadol for the preparation of pain medication
MX2011007930A (es) Conjugados de insulina cristalina.
NZ602925A (en) Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
IL185808A0 (en) Amide-substituted 8-n-benzimidazoles, metohd for the production thereof, and use of the same as medicaments
NZ603319A (en) Diabetes therapy
MY151048A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
IN2012DN02805A (https=)
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
IN2012DN01233A (https=)
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
PH12013502262A1 (en) Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
UA102432C2 (ru) Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
MX2009007247A (es) Metodo para el tratamiento de afecciones asociadas con actividad aumentada de 5-lipoxigenasa y/o leucotrienos.
NZ706740A (en) Use of vap-1 inhibitors for treating fibrotic conditions
PH12013500361A1 (en) Preventive or therapeutic agent for fibrosis
IL198202A0 (en) Peptide-cytotoxic conjugates
TW200833343A (en) Novel therapeutic utilization for the treatment of leukaemias
WO2011056850A3 (en) Linaclotide for the treatment of chronic constipation
MX2010004315A (es) Compuestos para inhibir la actividad de quinesina ksp.
MX2008001506A (es) Uso de sales de triotropio en el tratamiento de asma severa persistente.
MY146362A (en) Use of tiotropium salts in the treatment of moderate persistent asthma

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 25 MAR 2017 BY COMPUTER PACKAGES INC

Effective date: 20140328

LAPS Patent lapsed